Compare Nutanix Inc (NTNX) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutanix Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Nutanix Inc trades at $54 (market cap $14.90B), while State Street SPDR S&P Biotech ETF trades at $154.38. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.
| NTNX | XBI | |
|---|---|---|
Market Cap | $14.90B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $81.12 | $164.28 |
52-Week Low | $34.41 | $85.16 |
Enterprise Value | $14.41B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutanix (NTNX) trades at $55.11, up slightly by 0.05% today, with a bullish technical trend and strong analyst support. The company reported consistent earnings beats in recent quarters, with Q1 2026 EPS of $0.47 exceeding expectations. Revenue growth is projected to rise from $2.54 billion in 2025 to $2.7 billion in 2026, while net income margin improves to 10.03%. Recent news highlights partnerships and NVIDIA certification for its storage solutions, reinforcing its hybrid cloud positioning.
The outlook for NTNX is positive, driven by earnings momentum and strategic initiatives in AI infrastructure. Investment opportunities include potential upside to the $57.80 consensus price target and expanding profit margins. Key risks involve competitive pressures in cloud computing and reliance on enterprise spending cycles, which could impact growth if macroeconomic conditions weaken.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
